// App-Quantinova.ai

1074 : Shortened therapy of 8 weeks duration with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with acute and recent genotype 1 HCV infection: The TARGET3D Study

Researchers

Presenter

  • Marianne Martinello

Principal Investigators

  • Sanjay Bhagani

  • Edward J. Gane

  • Chloe Orkin

  • Graham Cooke

  • Ranjababu Kulasegaram

  • David Shaw

  • Margaret Hellard

  • Elise Tu

  • Ecaterina Filep

  • Kathy Petoumenos

  • Philippa Marks

  • Jason Grebely

  • Gregory J. Dore

  • Mark Nelson

  • Gail Matthews

Medical Centers

  • Viral Hepatitis Clinical Research Program, The Kirby Institute, Sydney, NSW, Australia

  • St Vincents Hospital, Sydney, Australia

  • The Royal Marsden Hospital, London, United Kingdom

  • Auckland City Hospital, Auckland, New Zealand

  • IMS Health, London, United Kingdom

  • Guy's Hospital, London, United Kingdom

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Royal Adelaide Hospital, Adelaide, Australia

  • The Alfred Hospital, Melbourne, Australia

  • Chelsea and Westminster Hospital, London, United Kingdom

Locations

  • Australia

  • United Kingdom

  • New Zealand

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Hepatitis C

Biomarkers

  • Alanine transaminase

Drug/Treatment

  • paritaprevir

  • ombitasvir

  • Exviera

  • Ritonavir

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved